Business Wire

HENLEY-&-PARTNERS

27.5.2021 07:02:06 CEST | Business Wire | Press release

Share
Thailand Elite’s Real Estate Partnership Set to Attract Foreign Investors Keen on Relocating and Owning Property in Thailand

Thailand’s sought-after Thailand Elite Residence Program which saw a sharp spike in applications throughout the Covid-19 pandemic in 2020, is set to be even more attractive to foreign investors following a new partnership with more than 10 leading real estate developers in Thailand as part of its Elite Flexible One (EFO) offering.

According to Mr. Somchai Soongswang, President of Thailand Privilege Card Co., Ltd ., the operator of Thailand Elite Card, “This pivotal partnership is expected to boost the property sector in Thailand through creating a multi-faceted return for international investors. The EFO option under the privileged entry visa program is of particular interest for applicants who are keen on investing in property either for residence or as an investment. The investors not only gain a return on their property investment but the inherent business & lifestyle benefits of Thai residence”

Each participating developer has a broad and deep selection of available property projects for foreign investors to choose from. Property purchases valued at the minimum of 10 million baht, will afford the buyer consideration for membership of Elite Flexible One, a five-year privilege entry visa – a similar five-year visa (Elite Easy Access) would normally cost THB 600,000 or approximately USD 19,000. The membership not only offers ease of entry into Thailand along with a wide range of VIP benefits, but also business and lifestyle services and rewards as offered by the developer partners to ensure members get the most out of residing in Thailand.

Thailand’s property market has long been considered stable and attractive, both in the form of rental yields, which can reach 8% in Bangkok, as well as capital gains on property value, with return on investment exceeding 10% per annum. Property analysts have predicted that the luxury housing market will be one of the fastest recovering segments as lockdown restrictions eased, with further market recovery expected to continue upon the resumption of freer international travel.

As condo developers are focused on clearing unsold inventory at pre-launch prices, these ready-to-move-into projects offer impressive value. Thai luxury real estate therefore represents a remarkable investment opportunity. Among the developers participating in the limited two-year scheme are well known names such as Sansiri, Ananda Development, AP (Thailand), Origin Property, Raimon Land and Charn Issara Development. There are over 45 projects available including those located in Bangkok’s upscale residential areas which includes Sukhumvit, Silom, Sathorn, and Asoke.

According to Dominic Volek, Group Head of Private Clients at Henley & Partners , the global concessionaire for Thailand Elite, “Savvy investors are now realizing that diversification is as relevant to lifestyle planning as it is to wealth management. As they reevaluate their priorities and seek alternative options for residence, the Thailand Elite Residence Program is often a top choice as it is a safe, prosperous country with an excellent quality of life.”

Since Henley & Partners became the official global concessionaire, the Thailand Elite Residence Program has expanded considerably and now has over 13,000 members. The first of its kind worldwide, the program is managed by Thailand Privilege Card Co. Ltd and offers applicants privilege entry visas, which include a wide range of VIP benefits. The program provides a multiple-entry visa to qualified applicants, allowing them to visit and reside in Thailand for a period of between five and twenty years, at a one-time cost of between THB 600,000 (approximately USD 19,000) and THB 2.14 million (approximately USD 68,000), depending on the option chosen. Benefits include airport limo services and lounge access, expedited immigration formalities, access to world-class healthcare services, dedicated concierge, and various privileges across hotels, shopping centers, golf courses, and more.

Henley & Partners caters to all clients interested in the program, either in person, via one of its offices globally, or virtually, via its online portal, thailandelite-direct.com .

Social Media:

https://www.facebook.com/HenleyPartners/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

Digital Reef Turns to Vertical Farming to Reduce Data Centre Footprint in Partnership With Elevate Farms and Xange.com to Provide Digital Measurement, Reporting and Verification of Project's Environmental Impact Within the Reef Origin Ecosystem23.10.2026 13:12:00 CEST | Press release

The collaboration leverages Elevate Farms’ proprietary vertical farming technology reducing water consumption, land usage and carbon emissions. Elevate Farms Inc. and Digital Reef Ltd partnership supports mitigating environmental impact of global data centre expansion establishing a framework for Digital Reef’s infrastructure pipeline to support and utilize environmental assets generated by Elevate Farms' high-yield, closed-loop vertical farming operations. Traditional agriculture supply chains are replaced with optimized indoor facilities significantly reducing food production carbon emissions, water waste and local land constraints. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022393352/en/ Elevate Farms technology offers part of the solution to climate impact isolating food production from traditional agricultural farming variables saving over 95% of standard water requirements and significantly reducing farmland req

SLB Announces Third-Quarter 2026 Results23.10.2026 12:50:00 CEST | Press release

Revenue of $9.45 billion increased 5% sequentially and 6% year on year GAAP EPS of $0.49 decreased 6% sequentially and 2% year on year EPS, excluding charges and credits, of $0.64 increased 16% sequentially and decreased 7% year on year Net income attributable to SLB of $735 million decreased 6% sequentially and 1% year on year Adjusted EBITDA of $2.07 billion increased 9% sequentially and was essentially flat year on year Cash flow from operations was $1.51 billion and free cash flow was $828 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the third-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021694458/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2026Jun. 30, 2026Sept. 30, 2025SequentialYear-on-yearRevenue $9,449 $8,972 $8,928 5

EZVIZ’s Smart Entry Solutions Have Consecutively Clinched the European Product Design Award and the Golden Pin Design Award, Indicating a Shift From Home Security to Living Enjoyment23.10.2026 11:58:00 CEST | Press release

EZVIZ’s smart lock and AI-powered doorbell remained in the spotlight after IFA for bagging two world-class awards. The EP8 Ultra AI-powered video doorbell won the European Product Design Award 2026 (EPDA 2026), keeping leading in user-centric AI. Meanwhile, the DL50FVX smart lock was named the 2026 Golden Pin Design Award (GPDA) laureate for its intuitive access management and entered the finalist of the Best Design Awards. The growing prestige of EZVIZ’s smart home access management lineup marks a new chapter of providing living experiences with multi-level interaction, modern aesthetics, and emotional care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022441786/en/ Two representative models from EZVIZ's smart entry family take home prestigious awards for user-centric innovation. Founded in 2016, the EPDA aims to recognize well-thought-out products that break with tradition and improve everyday life. Continually refres

Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines23.10.2026 07:00:00 CEST | Press release

The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults1,2 The approval is based on phase III results from a local clinical trial conducted in China as well as global READY clinical trials, with local results reinforcing that Relfydess delivers significant improvements in frown lines, with a fast onset of action as early as day one, and sustained results for up to six months in some patients3-7 This approval underscores Galderma’s continued leadership in the Asia-Pacific region and further expands the global reach of Relfydess, which is already authorized in more than 35 markets worldwide Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye